mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer

Small cell lung cancer (SCLC) is a recalcitrant malignancy with limited treatment options. Bromodomain and extraterminal domain inhibitors (BETis) have shown promising preclinical activity in SCLC, but the broad sensitivity spectrum limits their clinical prospects. Here, we performed unbiased high-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumari, Anju, Gesumaria, Lisa, Liu, Yan-Jin, Hughitt, V. Keith, Zhang, Xiaohu, Ceribelli, Michele, Wilson, Kelli M., Klumpp-Thomas, Carleen, Chen, Lu, McKnight, Crystal, Itkin, Zina, Thomas, Craig J., Mock, Beverly A., Schrump, David S., Chen, Haobin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077471/
https://www.ncbi.nlm.nih.gov/pubmed/36883564
http://dx.doi.org/10.1172/jci.insight.156657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077471/
https://www.ncbi.nlm.nih.gov/pubmed/36883564
http://dx.doi.org/10.1172/jci.insight.156657

Ejemplares similares